INTRODUCTION: Neuroectodermal tumors in general demonstrate high and dense expression of the somatostatin receptor subtype 2 (sst₂). It controls proliferation of both normal and neoplastic cells. sst₂ has thus been suggested as a therapeutic target and prognostic marker for certain malignancies. METHODS: To assess global expression patterns of sst 2 mRNA, we evaluated normal (n = 353) and tumor tissues (n = 340) derived from previously published gene expression profiling studies. These analyses demonstrated specific upregulation of sst 2 mRNA in medulloblastoma (p < 0.001). sst₂ protein was investigated by immunohistochemistry in two independent cohorts. RESULTS: Correlation of sst₂ protein expression with clinicopathological variables revealed significantly higher levels in medulloblastoma (p < 0.05) compared with CNS-PNET, ependymoma, or pilocytic astrocytoma. The non-SHH medulloblastoma subgroup tumors showed particularly high expression of sst₂, when compared to other tumors and normal tissues. Furthermore, we detected a significant survival benefit in children with tumors exhibiting high sst₂ expression (p = 0.02) in this screening set. A similar trend was observed in a validation cohort including 240 independent medulloblastoma samples. CONCLUSION: sst₂ is highly expressed in medulloblastoma and deserves further evaluation in the setting of prospective trials, given its potential utility as a prognostic marker and a therapeutic target.
INTRODUCTION:Neuroectodermal tumors in general demonstrate high and dense expression of the somatostatin receptor subtype 2 (sst₂). It controls proliferation of both normal and neoplastic cells. sst₂ has thus been suggested as a therapeutic target and prognostic marker for certain malignancies. METHODS: To assess global expression patterns of sst 2 mRNA, we evaluated normal (n = 353) and tumor tissues (n = 340) derived from previously published gene expression profiling studies. These analyses demonstrated specific upregulation of sst 2 mRNA in medulloblastoma (p < 0.001). sst₂ protein was investigated by immunohistochemistry in two independent cohorts. RESULTS: Correlation of sst₂ protein expression with clinicopathological variables revealed significantly higher levels in medulloblastoma (p < 0.05) compared with CNS-PNET, ependymoma, or pilocytic astrocytoma. The non-SHHmedulloblastoma subgroup tumors showed particularly high expression of sst₂, when compared to other tumors and normal tissues. Furthermore, we detected a significant survival benefit in children with tumors exhibiting high sst₂ expression (p = 0.02) in this screening set. A similar trend was observed in a validation cohort including 240 independent medulloblastoma samples. CONCLUSION: sst₂ is highly expressed in medulloblastoma and deserves further evaluation in the setting of prospective trials, given its potential utility as a prognostic marker and a therapeutic target.
Authors: Marc Remke; Thomas Hielscher; Paul A Northcott; Hendrik Witt; Marina Ryzhova; Andrea Wittmann; Axel Benner; Andreas von Deimling; Wolfram Scheurlen; Arie Perry; Sidney Croul; Andreas E Kulozik; Peter Lichter; Michael D Taylor; Stefan M Pfister; Andrey Korshunov Journal: J Clin Oncol Date: 2011-05-31 Impact factor: 44.544
Authors: Yoon-Jae Cho; Aviad Tsherniak; Pablo Tamayo; Sandro Santagata; Azra Ligon; Heidi Greulich; Rameen Berhoukim; Vladimir Amani; Liliana Goumnerova; Charles G Eberhart; Ching C Lau; James M Olson; Richard J Gilbertson; Amar Gajjar; Olivier Delattre; Marcel Kool; Keith Ligon; Matthew Meyerson; Jill P Mesirov; Scott L Pomeroy Journal: J Clin Oncol Date: 2010-11-22 Impact factor: 44.544
Authors: Andrey Korshunov; Marc Remke; Wiebke Werft; Axel Benner; Marina Ryzhova; Hendrik Witt; Dominik Sturm; Andrea Wittmann; Anna Schöttler; Jörg Felsberg; Guido Reifenberger; Stefan Rutkowski; Wolfram Scheurlen; Andreas E Kulozik; Andreas von Deimling; Peter Lichter; Stefan M Pfister Journal: J Clin Oncol Date: 2010-05-17 Impact factor: 44.544
Authors: J Guyotat; J Champier; A Jouvet; F Signorelli; C Houzard; P Bret; G Saint Pierre; M Fevre Montange Journal: Int J Cancer Date: 2001-05-20 Impact factor: 7.396
Authors: P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: P Cervera; C Videau; C Viollet; C Petrucci; J Lacombe; R Winsky-Sommerer; Z Csaba; L Helboe; C Daumas-Duport; J C Reubi; J Epelbaum Journal: J Neuroendocrinol Date: 2002-06 Impact factor: 3.627
Authors: R Gilbertson; C Wickramasinghe; R Hernan; V Balaji; D Hunt; D Jones-Wallace; J Crolla; R Perry; J Lunec; A Pearson; D Ellison Journal: Br J Cancer Date: 2001-09-01 Impact factor: 7.640
Authors: Chenue Abongwa; Sarah Mott; Blanca Schafer; Parren McNeely; Ghada Abusin; Thomas O'Dorisio; Gideon Zamba; M Sue O'Dorisio; Yusuf Menda Journal: Am J Nucl Med Mol Imaging Date: 2017-11-01
Authors: Kelsey L Whittier; Erin A Boese; Katherine N Gibson-Corley; Patricia A Kirby; Benjamin W Darbro; Qining Qian; Wendy J Ingram; Thomas Robertson; Marc Remke; Michael D Taylor; M Sue O'Dorisio Journal: Acta Neuropathol Commun Date: 2013-10-10 Impact factor: 7.801